Advanced breast cancer. A comparative evaluation of epirubicin and doxorubicin (Adriamycin): Preliminary report of the EORTC breast cancer cooperative group

A. T. Van Oosterom, H. T. Mouridsen, J. Wildiers, J. Blonk-Van Der Wijst, G. Cocconi, L. V M Beex, N. Rotmensz, R. Sylvester

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

A preliminary report on an uncompleted Phase III study following results obtained from a Phase II study is presented. In the Phase II study epirubicin 90 mg/m2 i.v. every three weeks and doxorubicin (Adriamycin) 75 mg/m2 i.v. every three weeks were given, the myelotoxicity expected and found being approximately the same for each group. There were two complete and eight partial responses obtained in the epirubicin group of 31 patients and five complete and five partial responses obtained from the 33 patients on doxorubicin. The median duration of complete response in the epirubicin group was 38 1/2 weeks and 24 weeks for doxorubicin. The overall response rate was 32% for epirubicin and 30% for doxorubicin. In the Phase III study, 30 patients out of 90 have given responses - seven complete, 23 partial. Only two patients on epirubicin and four on doxorubicin had a nadir platelet count below 50,000. With respect to myelotoxicity the dosages of 90 and 75 mg/m2 for epirubicin and doxorubicin respectively appeared to be adequate. The antitumour activities of both compounds appear to be equal. Oral toxicity and diarrhoea appear to be slightly less with epirubicin.

Original languageEnglish
Pages (from-to)131-137
Number of pages7
JournalClinical Trials Journal
Volume24
Issue numberSUPPL. 1
Publication statusPublished - 1987

Fingerprint

Epirubicin
Doxorubicin
Breast Neoplasms
Platelet Count
Diarrhea

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Van Oosterom, A. T., Mouridsen, H. T., Wildiers, J., Blonk-Van Der Wijst, J., Cocconi, G., Beex, L. V. M., ... Sylvester, R. (1987). Advanced breast cancer. A comparative evaluation of epirubicin and doxorubicin (Adriamycin): Preliminary report of the EORTC breast cancer cooperative group. Clinical Trials Journal, 24(SUPPL. 1), 131-137.

Advanced breast cancer. A comparative evaluation of epirubicin and doxorubicin (Adriamycin) : Preliminary report of the EORTC breast cancer cooperative group. / Van Oosterom, A. T.; Mouridsen, H. T.; Wildiers, J.; Blonk-Van Der Wijst, J.; Cocconi, G.; Beex, L. V M; Rotmensz, N.; Sylvester, R.

In: Clinical Trials Journal, Vol. 24, No. SUPPL. 1, 1987, p. 131-137.

Research output: Contribution to journalArticle

Van Oosterom, AT, Mouridsen, HT, Wildiers, J, Blonk-Van Der Wijst, J, Cocconi, G, Beex, LVM, Rotmensz, N & Sylvester, R 1987, 'Advanced breast cancer. A comparative evaluation of epirubicin and doxorubicin (Adriamycin): Preliminary report of the EORTC breast cancer cooperative group', Clinical Trials Journal, vol. 24, no. SUPPL. 1, pp. 131-137.
Van Oosterom AT, Mouridsen HT, Wildiers J, Blonk-Van Der Wijst J, Cocconi G, Beex LVM et al. Advanced breast cancer. A comparative evaluation of epirubicin and doxorubicin (Adriamycin): Preliminary report of the EORTC breast cancer cooperative group. Clinical Trials Journal. 1987;24(SUPPL. 1):131-137.
Van Oosterom, A. T. ; Mouridsen, H. T. ; Wildiers, J. ; Blonk-Van Der Wijst, J. ; Cocconi, G. ; Beex, L. V M ; Rotmensz, N. ; Sylvester, R. / Advanced breast cancer. A comparative evaluation of epirubicin and doxorubicin (Adriamycin) : Preliminary report of the EORTC breast cancer cooperative group. In: Clinical Trials Journal. 1987 ; Vol. 24, No. SUPPL. 1. pp. 131-137.
@article{4e8b3b314a73416e846cfe6230e35ae0,
title = "Advanced breast cancer. A comparative evaluation of epirubicin and doxorubicin (Adriamycin): Preliminary report of the EORTC breast cancer cooperative group",
abstract = "A preliminary report on an uncompleted Phase III study following results obtained from a Phase II study is presented. In the Phase II study epirubicin 90 mg/m2 i.v. every three weeks and doxorubicin (Adriamycin) 75 mg/m2 i.v. every three weeks were given, the myelotoxicity expected and found being approximately the same for each group. There were two complete and eight partial responses obtained in the epirubicin group of 31 patients and five complete and five partial responses obtained from the 33 patients on doxorubicin. The median duration of complete response in the epirubicin group was 38 1/2 weeks and 24 weeks for doxorubicin. The overall response rate was 32{\%} for epirubicin and 30{\%} for doxorubicin. In the Phase III study, 30 patients out of 90 have given responses - seven complete, 23 partial. Only two patients on epirubicin and four on doxorubicin had a nadir platelet count below 50,000. With respect to myelotoxicity the dosages of 90 and 75 mg/m2 for epirubicin and doxorubicin respectively appeared to be adequate. The antitumour activities of both compounds appear to be equal. Oral toxicity and diarrhoea appear to be slightly less with epirubicin.",
author = "{Van Oosterom}, {A. T.} and Mouridsen, {H. T.} and J. Wildiers and {Blonk-Van Der Wijst}, J. and G. Cocconi and Beex, {L. V M} and N. Rotmensz and R. Sylvester",
year = "1987",
language = "English",
volume = "24",
pages = "131--137",
journal = "Clinical Trials Journal",
issn = "0009-9325",
publisher = "Elsevier BV",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Advanced breast cancer. A comparative evaluation of epirubicin and doxorubicin (Adriamycin)

T2 - Preliminary report of the EORTC breast cancer cooperative group

AU - Van Oosterom, A. T.

AU - Mouridsen, H. T.

AU - Wildiers, J.

AU - Blonk-Van Der Wijst, J.

AU - Cocconi, G.

AU - Beex, L. V M

AU - Rotmensz, N.

AU - Sylvester, R.

PY - 1987

Y1 - 1987

N2 - A preliminary report on an uncompleted Phase III study following results obtained from a Phase II study is presented. In the Phase II study epirubicin 90 mg/m2 i.v. every three weeks and doxorubicin (Adriamycin) 75 mg/m2 i.v. every three weeks were given, the myelotoxicity expected and found being approximately the same for each group. There were two complete and eight partial responses obtained in the epirubicin group of 31 patients and five complete and five partial responses obtained from the 33 patients on doxorubicin. The median duration of complete response in the epirubicin group was 38 1/2 weeks and 24 weeks for doxorubicin. The overall response rate was 32% for epirubicin and 30% for doxorubicin. In the Phase III study, 30 patients out of 90 have given responses - seven complete, 23 partial. Only two patients on epirubicin and four on doxorubicin had a nadir platelet count below 50,000. With respect to myelotoxicity the dosages of 90 and 75 mg/m2 for epirubicin and doxorubicin respectively appeared to be adequate. The antitumour activities of both compounds appear to be equal. Oral toxicity and diarrhoea appear to be slightly less with epirubicin.

AB - A preliminary report on an uncompleted Phase III study following results obtained from a Phase II study is presented. In the Phase II study epirubicin 90 mg/m2 i.v. every three weeks and doxorubicin (Adriamycin) 75 mg/m2 i.v. every three weeks were given, the myelotoxicity expected and found being approximately the same for each group. There were two complete and eight partial responses obtained in the epirubicin group of 31 patients and five complete and five partial responses obtained from the 33 patients on doxorubicin. The median duration of complete response in the epirubicin group was 38 1/2 weeks and 24 weeks for doxorubicin. The overall response rate was 32% for epirubicin and 30% for doxorubicin. In the Phase III study, 30 patients out of 90 have given responses - seven complete, 23 partial. Only two patients on epirubicin and four on doxorubicin had a nadir platelet count below 50,000. With respect to myelotoxicity the dosages of 90 and 75 mg/m2 for epirubicin and doxorubicin respectively appeared to be adequate. The antitumour activities of both compounds appear to be equal. Oral toxicity and diarrhoea appear to be slightly less with epirubicin.

UR - http://www.scopus.com/inward/record.url?scp=0023606104&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023606104&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0023606104

VL - 24

SP - 131

EP - 137

JO - Clinical Trials Journal

JF - Clinical Trials Journal

SN - 0009-9325

IS - SUPPL. 1

ER -